Hong Kong Biotech Startup Develops HIV Cure Vaccine

Hong Kong-based biotech startup ImmunoCure has announced the development of a vaccine capable of curing HIV, the virus that leads to AIDS. The company reported promising results from recent clinical trials, marking a significant step toward making the vaccine available to patients.

These trials involved 45 participants at Shenzhen Third People’s Hospital. Unlike traditional vaccines that are preventive, ImmunoCure has developed a therapeutic vaccine designed to treat infections after they occur.

The company stated that the vaccine effectively boosted T-cell (white blood cell) responses in a majority of participants, showcasing its potential as a groundbreaking treatment.